BRIEF-Merck Enters Exclusive Global License Deal With Scibrunch Therapeutics For SPR2015
Reuters2026/09/28 11:07Sept 28 (Reuters) - Merck & Co Inc MRK.N:
SAYS MERCK ENTERS EXCLUSIVE GLOBAL LICENSE DEAL WITH SCIBRUNCH THERAPEUTICS FOR INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR SPR2015
Further company coverage: MRK.N
(Reporting by Beijing Newsroom)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian Dollar remains subdued near two-month lows as falling oil prices weigh
Jamie Dimon Says the Dollar Only Stays Dominant if the US Makes Trade Deals
Wall Street Tokenization Explained: Will Blockchain Replace Today's Stock Trading Stack?
British Pound seems vulnerable near two-month low as USD bulls eye US PCE and GDP
Crypto prices
More
